Phathom Pharmaceuticals (PHAT) Cash from Financing Activities (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has reported Cash from Financing Activities for 9 consecutive years, with $3.6 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash from Financing Activities rose 4338.75% year-over-year to $3.6 million; the TTM figure through Jun 2026 stood at $69.8 million (down 52.88% YoY), while the FY2025 annual figure was -$288000.0, down 100.16% from the prior year.
• Cash from Financing Activities fell to $3.6 million in Q2 2026 per PHAT's latest filing, from $66.6 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $212.0 million in Q4 2023 and bottomed at -$271000.0 in Q3 2025.
• Historically, Cash from Financing Activities has averaged $46.1 million across 5 years, with a median of $19.3 million in 2022.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities surged 938800.0% — and 2025, when it slumped 100.37%.
• Phathom Pharmaceuticals' Cash from Financing Activities stood at $24.6 million in 2022, then surged by 761.9% to $212.0 million in 2023, then slumped by 87.71% to $26.0 million in 2024, then plunged by 100.37% to -$97000.0 in 2025, then soared by 3760.82% to $3.6 million in 2026.
• Business Quant data shows PHAT's Cash from Financing Activities at $3.6 million in Q2 2026, $66.6 million in Q1 2026, and -$97000.0 in Q4 2025.